Gastroenterologische Schwerpunktpraxis Prof. Dr. Ludwig & Dr. med. Güthle
- Address
- Zeppelinstraße 16, 89160 Dornstadt, Germany
Digestive System Diseases – Ulcerative Colitis
The Gastroenterologische Schwerpunktpraxis Prof. Dr. Ludwig & Dr. med. Güthle in Dornstadt concentrates on improving care for ulcerative colitis, a chronic inflammatory disorder of the digestive system. Ongoing research evaluates the oral controlled‑ileocolonic‑release nicotinamide (CICR‑NAM) and the biologic agent mirikizumab to achieve sustained remission and mucosal healing.
- Oral controlled‑ileocolonic‑release nicotinamide therapy
- Top‑down biologic approach with mirikizumab
- Comparison with standard azathioprine treatment
- Assessment of symptomatic remission and endoscopic response
- Evaluation of comprehensive disease control at one year
With a focused investigator team, the site conducts patient‑centered trials that compare innovative therapies against established care, aiming to deliver better long‑term outcomes for individuals with mild to moderate or newly diagnosed moderate‑to‑severe ulcerative colitis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gastroenterologische Schwerpunktpraxis Prof. Dr. Ludwig & Dr. med. Güthle
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy of Mirikizumab Versus Azathioprine and Glucocorticoids in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: A 52-Week Randomized Trial | Universitaetsklinikum Schleswig-Holstein AöR | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azathioprine | 1 | Unknown | 2025-12-05 | 2025-12-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.